Stuart A. Arbuckle - 17 May 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Comm & Ops Officer
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 May 2021
Net transactions value
-$23,589
Form type
4
Filing time
19 May 2021, 16:04:22 UTC
Next filing
11 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $1,507 -7 -0.02% $215.33 41,205 17 May 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale $18,607 -86 -0.21% $216.36 41,119 17 May 2021 Direct F1, F3, F4
transaction VRTX Common Stock Sale $3,474 -16 -0.04% $217.15 41,103 17 May 2021 Direct F1, F3, F5
holding VRTX Common Stock 140 17 May 2021 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $215.33 (range $214.82 to $215.80).
F3 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $216.36 (range $215.82 to $216.76).
F5 Open market sales reported on this line occurred at a weighted average price of $217.15 (range $216.83 to $217.32).